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Gamma-tocotrienol, a major component of tocotrienol-rich fraction of palm oil, has been suggested to exhibit bone protective
effects in vivo. However, the effects of 𝛾-tocotrienol on osteoblast cells are still unclear. In this study, the effects of 𝛾-tocotrienol
on the proliferation, differentiation, and mineralization in osteoblastic MC3T3-E1 cells were investigated. Our results showed that
𝛾-tocotrienol (2–8 𝜇mol/L) significantly improved the cell proliferation (𝑝 < 0.05), but it did not affect cell cycle progression.
𝛾-Tocotrienol significantly increased alkaline phosphatase (ALP) activity (𝑝 < 0.05), secretion levels of osteocalcin (OC) and
osteonectin (ON), and mRNA levels of collagen type I (Col I) of MC3T3-E1 cells. Meanwhile, we found that 𝛾-tocotrienol is
promoted in differentiation MC3T3-E1 cells by upregulation of the expression of Runx2 protein. Moreover, the number of bone
nodules increased over 2.5-fold in cells treated with 𝛾-tocotrienol (2–8 𝜇mol/L) for 24 d compared to control group. These results
indicated that 𝛾-tocotrienol at low dose levels, especially 4𝜇mol/L, could markedly enhance the osteoblastic function by increasing
the proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. Moreover, our data also indicated that Runx2
proteinmay be involved in these effects. Further studies are needed to determine the potential of 𝛾-tocotrienol as an antiosteoporotic
agent.
1. Introduction
Osteoporosis affects 1/3 of women and 1/5 of men over the
age of 50 years worldwide; it affects 75% of aged population in
Europe, USA, and Japan [1]; and in China alone, there are 0.21
billion of people with low bone density [2]. Osteoporosis is
characterized by low bone density and deterioration of bone
microarchitecture [3]. Osteoporosis causes progressive bone
loss and arises from an imbalance of bone resorption and
formation in the bone remodeling process. There are many
factors which can cause osteoporosis such as menopause,
aging, thyroid diseases, and calcium deficiency [4].
Currently, most drugs for the treatment of osteoporosis
focus on improvement of bone resorption, via either reducing
osteoclast number (such as bisphosphonates and estrogen)
or inhibition of osteoclast activity (such as cathepsin K
inhibitors). However, they have little ability to stimulate new
bone synthesis [1, 5–7]. Since new bone formation depends
primarily on the function of osteoblasts, the agents acting by
either increasing the proliferation or inducing differentiation
of the osteoblasts could enhance bone formation [8, 9].
Furthermore, the potential bone-forming agents or drugs
currently available either may have serious side-effects or
may not improve bone quality to reduce the susceptibility to
fracture. Thus, the discovery of natural dietary compounds
that promote bone formation may be able to avoid the
occurrence of the adverse effects of traditional drug in
humans and will be of great interest.
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Figure 1: Effect of 𝛾-tocotrienol on viability in MC3T3-E1 cells. (a) The structure of tocopherol and tocotrienol. (b) Cells were exposed to
different doses of 𝛾-tocotrienol for 24, 48, or 72 h. Cell viability was determined by MTT assay. (c) Cells were treated with different doses
of 𝛾-tocotrienol for 24, 48, and 72 h. Images were captured by phase contrast microscopy (200x). (d) Cells were stained with DAPI dye for
measuring nuclear morphological alteration (DAPI, 200x). Data are expressed as mean ± SD (𝑛 = 3). ∗𝑝 < 0.05, compared to the control
group. B: blank control; C: ethanol control.
Tocotrienols and tocopherols, two subclasses of vitamin
E, are abundant in food ingredients such as palm oil, rice
bran oil, barley, corn, oats, rye, and wheat [10, 11]. Each of
them has four stereoisomers, respectively, namely, 𝛼-, 𝛽-, 𝛾-,
and 𝛿-tocopherols or tocotrienols (Figure 1(a)). Tocopherols
contain a saturated phytol side chain in the chroman ring.
Tocotrienols differ from the tocopherols in that they contain
three double bonds in the side chain [12]. In previous studies,
tocotrienols have been shown to have better bone protective
effects when compared to 𝛼-tocopherol in animal osteo-
porosis models [13–19]. Furthermore, studies also showed
that tocotrienols were able to prevent and even reverse
osteoporosis in estrogen deficiency, testosterone deficiency,
glucocorticoid excess, and nicotine exposure [15–17, 20–23].
Previous study demonstrated that palm tocotrienol is even
more effective than calcium in preventing bone loss caused
by estrogen deficiency [24]. Tocotrienols showed a better
bone anabolic action than tocopherol in normal male rats
[14, 25]. The protective mechanism of tocotrienols on bone
was thought to be contributed by its antioxidant property
[17, 18, 26].
Although in vivo studies have shown that tocotrienols
exhibit bone protective activity, there is paucity of in vitro
studies to determine the effect of tocotrienols on bone
cells, especially tocotrienol isomers [15–17, 20–25, 27]. 𝛾-
Tocotrienol, the most abundant isomer in palm oil (up to
49% of the vitamin E) [28], was the most potent isomer of
tocotrienols in promotion bone formation and protection
in the in vivo studies [14, 29]. However, few studies had
reported the direct evidence on the effect of 𝛾-tocotrienol in
osteoblast function. The purpose of the present study was to
understand the effects of 𝛾-tocotrienol on cell proliferation,
differentiation, and mineralization in osteoblastic MC3T3-E1
cells.
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Table 1: Sequences of primers for real-time PCR.
Gene Forward primer (5󸀠-3󸀠) Reverse primer (5󸀠-3󸀠) Size (bp)
GAPDH CCCAGAAGACTGTGGATGG GGATGCAGGGATGATGTTCT 81
Ki-67 GACAGCTTCCAAAGCTCACC GTGTCCTTAGCTGCCTCCTG 228
PCNA TGGAATCCCAGAACAGGAG CCAATGTGGCTAAGGTCTCG 87
Col I GCATGGCCAAGAAGACATCC CCTCGGGTTTCCACGTCTC 83
Runx-2 GCCGGGAATGATGAGAACTA TGGGGAGGATTTGTGAAGAC 155
2. Materials and Methods
2.1. Materials. Osteoblastic MC3T3-E1 cells were purchased
from the Cell Bank of the Chinese Academy of Sciences
(Shanghai, China). Fetal bovine serum (FBS) and 𝛼-
minimum essential medium (𝛼-MEM) were purchased from
Gibco Life Technologies Co. (Carlsbad, CA, USA). 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), LiCl, propidium iodide (PI), and 4󸀠,6-diamidine-
2󸀠-phenylindole dihydrochloride (DAPI) were bought from
Sigma Aldrich (Kansas, MO, USA). 𝛾-Tocotrienol was
purchased from Cayman Chemical Co. (Ann Arbor, MI,
USA). Alizarin Red staining reagent kit was purchased from
GenMed Scientifics Inc. (USA). ALP reagent kit and ELISA
kit were bought from Nanjing Jiancheng Bioengineering
Institute (Nanjing, China). The MiniBEST Universal RNA
extraction kit and PrimeScript RT reagent kits were
purchased from Takara Biotech Co., Ltd. (Dalian, China).
Rabbit polyclonal antibodies for NAPDH, PCNA, and Runx-
2 and goat anti-rabbit secondary antibody were bought from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
2.2. Cell Culture. Cells were cultured in 𝛼-MEM containing
10% FBS at 37∘C in a humidified atmosphere containing 5%
CO
2
. When the cells reached subconfluence (about 24 h),
various concentrations of 𝛾-tocotrienol were added to the
medium containing 5% FBS. Stock solutions of 𝛾-tocotrienol
were prepared in absolute ethanol and stored at −20∘C. The
final ethanol concentration in all cultures was 0.05%.
2.3. Viability Assay. The effect of 𝛾-tocotrienol on cell
proliferation was investigated by MTT assay as previously
described with some modifications [30]. Briefly, MC3T3-E1
cells (1 × 104 cells/well) were seeded in the 96-well plates
overnight. The medium was removed and the cells were
treated with 200𝜇L of medium containing 𝛾-tocotrienol (1,
2, 4, 8, and 16 𝜇mol/L, resp.) for 24, 48, and 72 h. Each dose of
𝛾-tocotrienol was repeated in five wells. Twentymicroliters of
MTT (5mg/ml in PBS) was added to each well and incubated
at 37∘C for 4 h.Themediumwas carefully removed and 150𝜇L
of dimethyl sulfoxide was added to each well. The plates
were shaken for 10min and the absorbance at 490 nm was
measured in a microplate reader (BioTek Instruments, Inc.,
USA).The cell viability was indicated as the percentage of the
ODof samples to that of the control group, taking the viability
of the blank control cells as 100%.
2.4. Morphologic Observation. After treatment with various
concentrations of 𝛾-tocotrienol for the desired time, cell
morphological changes were observed by inverted micro-
scope. Changes of the nuclei were investigated by staining
the cells with fluorescent DNA-binding dyes. Briefly, cells
were harvested, washed with PBS, and fixed with 4% poly-
oxymethylene for 20min at 4∘C.Afterwashingwith PBS, cells
were incubated with DAPI (15 𝜇g/ml) for 15min in the dark
at room temperature. Images were taken using a fluorescence
microscope (Eclipse 80i, Nikon, Japan).
2.5. Cell Cycle Analysis. The cells were harvested, washed
three times with PBS, fixed with 70% cool ethanol for 2 h, and
stained with PI solution (500 𝜇L, 50 𝜇g/ml PI, and 50 𝜇g/ml
RNase in 1% NP-40 solution) for 30min in the dark at room
temperature. Cells (1 × 105) were analyzed by FAC Sort flow
cytometer (BDBiosciences, USA).The proportions in G
0
/G
1
,
S, and G
2
/M phases were analyzed using ModFit LT analysis
software.
2.6. Quantitative Real-Time qPCR. Total RNAs were ex-
tracted from each treatment using MiniBEST Universal
RNA Extraction kit according to the manufacturer’s instruc-
tion. Total RNA was reverse transcribed into cDNA using
PrimeScript RT reagent kits, following the manufacturer’s
instruction. Target gene expression was normalized to the
housekeeping gene glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH). The 2−ΔΔCt method was applied to calculate
relative gene expression when compared to the control group
[31]. The primers [32–35] used for real-time PCR were listed
in Table 1.
2.7. Western Blot Analysis. Protein expression levels were
investigated by Western blot method according to our pre-
vious study [36]. The total protein concentrations of each
sample were measured in a 550 Universal microplate reader
(Bio-Tek Instruments, Inc.) at 562 nm. For Western blotting,
100 𝜇g of protein was resolved on 10% polyacrylamide gels
and transferred to a nitrocellulosemembrane.Themembrane
was blocked in blocking buffer (1% BSA, 1% Tween 20 in
20mM Tris-buffered saline (TBS), pH 7.6) for 30min at
37∘C in a hybridization oven, incubated with appropriate
monoclonal or polyclonal primary antibody in blocking
buffer for 2 h at 37∘C or overnight at 4∘C. The membrane
was washed 3 × 5 times with Tris-buffered saline Tween
20 (TBST) followed by incubation with anti-mouse or anti-
rabbit secondary antibody at 37∘C for 1 h. The membrane
was washed 3 × 5 times with TBST and then washed with
TBS twice. Then the membrane was incubated with alkaline
phosphatase until an appropriate signal level was obtained.
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Protein bands were detected by FluorChem Imaging Systems
(Bio-Rad, Hercules, CA, USA).
2.8. ALP Activity Assay. Cells were exposed to different
concentrations of 𝛾-tocotrienol (2, 4, 8, and 16 𝜇mol/L) for
24, 48, and 72 h. Cells were harvested and incubated with 1%
Triton-100 in PBS. ALP activity was measured by ALP assay
kit according the manufacturer’s instruction. The protein
was also measured by the bicinchoninic acid (BCA) method
(Applygen Technologies, Inc.). ALP activity was standardized
as the relative percentage to control group.
2.9. OC, ON, and Col I ELISA Assays. After exposure
to different concentrations of 𝛾-tocotrienol (2, 4, 8, and
16 𝜇mol/L) for 3 and 6 d, OC, ON, and Col I secretion were
evaluated in the cultured medium by ELISA kit, according to
manufacturer’s instructions.The absorbance wasmeasured at
450 nm with a microplate reader (Eon, Bio-Tek Instruments,
USA).
2.10. Mineralization Analysis by Alizarin Red Staining. After
being exposed to 𝛾-tocotrienol (2, 4, 8, and 16 𝜇mol/L) for
8, 16, and 24 d, cells were stained with Alizarin Red kit
(GenMed Scientifics Inc., USA). Cells with orange red stain-
ing indicated calcium deposits. The results were observed
with a phase contrast microscope at a magnification of
×200. Alizarin Red was quantified in a solution of 20%
methanol and 10% acetic acid in water. After washing the
cells for 15min, the solution was transferred to a 96-well
plate and absorbance of Alizarin Red was measured by a
spectrophotometer at 450 nm.
2.11. Statistical Analysis. Statistical analysis was performed
using SPSS version 14.0 (SPSS, Inc., Chicago, IL, USA). The
data were expressed as mean ± SD. Differences between the
control and treated groups were evaluated by the one-way
analysis of variance (ANOVA) test with the Bonferroni post
hoc multiple comparisons and considered significant at 𝑝 <
0.05.
3. Results and Discussions
3.1. Effect of 𝛾-Tocotrienol on the Proliferation of MC3T3-E1
Cells. The effect of 𝛾-tocotrienol on cell viability was shown
in Figure 1(b). Cell viability was increased significantly in 𝛾-
tocotrienol (1–8 𝜇mol/L, especially at 4𝜇mol/L) groups when
compared to control groups. After treatment with 4 𝜇mol/L
𝛾-tocotrienol for 24, 48, and 72 h, cell viability increased by
83.3%, 40.9%, and 33.3%, respectively (𝑝 < 0.05). However,
cell viability was significantly inhibited by 𝛾-tocotrienol
at dosages above 16 𝜇mol/L (𝑝 < 0.05). Morphological
changes of control and treated cells are shown in Figure 1(c).
In control cells, irregular shapes were observed, such as
triangles, polygons, and long spindles with different length
pseudopodia. The cytoplasm was abundant and clear, and
the nuclei were large and clear. There was no significant
morphological change in cells treated with 𝛾-tocotrienol at
doses of 4–8𝜇mol/L for 24, 48, and 72 h. However, MC3T3-
E1 cells treated with 𝛾-tocotrienol at doses above 16 𝜇mol/L
for 48 and 72 h began to show deformation, shrinking, and
floating when compared with the control cells. The nuclear
morphological alteration of MC3T3-E1 cells was shown in
Figure 1(d); there were no nuclear morphological alteration
between control cells and 𝛾-tocotrienol- (2–8𝜇mol/L) treated
cells. However, typically apoptotic changes such as chromatin
condensation and nuclear fragmentation were found in cells
treated with 𝛾-tocotrienol at 16 𝜇mol/L for 72 h or 32 𝜇mol/L
for both 48 and 72 h (data not shown).
Treatment with 𝛾-tocotrienol (2–8 𝜇mol/L) for 24 and
48 h did not change the ratios of G0/G1, S, and G2/M
phase in MC3T3-E1 cells when compared to the control cells
(Figure 2(a)). However, it was significantly affected if the dose
of 𝛾-tocotrienol was more than 16 𝜇mol/L.The proportion in
G
0
/G
1
phase was changed from 57.85 to 64.61% in untreated
cells and from 85.74 to 80.08% in treated cells for 24 and
48 h, respectively, while S phase was changed from 31.26
to 25.63% in the control cells and from 6.34 to 11.46% in
treated cells for 24 and 48 h, respectively. The apoptotic rates
were 4.55% ± 0.72% and 14.26% ± 1.91% in cells treated
with 𝛾-tocotrienol (16 𝜇mol/L) for 24 and 48 h, respectively.
Our results showed that 𝛾-tocotrienol (2–8𝜇mol/L) could
promote osteoblast proliferation did not affect the cell cycle
distribution, and no cytotoxicity was observed in MC3T3-E1
cells. However, 16 𝜇mol/L and above of 𝛾-tocotrienol showed
the toxicity to osteoblast cells. The results are consistent
with previous studies [16, 37] which demonstrate that 𝛾-
tocotrienol, at low dosage, was better than 𝛼-tocopherol in
protecting rat osteoblasts against H
2
O
2
toxicity; but at high
dosage it was toxic to osteoblasts in rats [16]. It may be caused
by the fact that antioxidants, like 𝛾-tocotrienol, at a certain
dosage can become prooxidants [38]. The unsaturated side
chains of tocotrienols (Figure 1(a)) allow them to penetrate
more efficiently into the membrane lipid bilayer resulting in
a high antioxidant activity in comparison with tocopherols
[39].
PCNA, a nuclear protein that binds to DNA polymerase,
is a cell cycle regulator expressed in the nucleus of prolifer-
ating cells. PCNA is an accepted hallmark for cellular pro-
liferation [40, 41]. Ki-67, a protein expressed in proliferating
cells, may indicate a more robust marker of cell proliferation
than PCNA [16]. Ki-67 protein expression occurs during
the G
1
phase, increases during the cycle cell, and rapidly
declines after mitosis [42]. To further determine effects of
𝛾-tocotrienol on the proliferation of MC3T3-E1 cells, levels
of Ki-67 and PCNA were determined by real-time PCR and
Western blot.The results were shown in Figures 2(b) and 2(c);
mRNA levels of Ki-67 and PCNAwere obviously upregulated
by treatment with 2–8 𝜇mol/L of 𝛾-tocotrienol for 48 and
72 h. However, they were downregulated in cells treated
with 16 𝜇mol/L of 𝛾-tocotrienol. Furthermore, treatmentwith
2–4 𝜇mol/L of 𝛾-tocotrienol for 24 and 48 h significantly
increased the PCNA protein expression level in MC3T3-E1
in comparison with the control group. However, 16 𝜇mol/L
𝛾-tocotrienol decreased the expressive level of PCNA protein
(Figure 2(d)). The result indicated that 𝛾-tocotrienol at low
dosage could indirectly regulate the activation of osteoblast
proliferation and was consistent with MTT results.
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Figure 2: Effect of 𝛾-tocotrienol on cell cycle progression, relative mRNA, and protein levels of Ki67 and PCNA in MC3T3-E1 cells. (a) Cells
were treated with different doses of 𝛾-tocotrienol for 24 and 48 h. Cells were fixed by 70% ethanol and stained by propidium iodide dye.
The distribution of cell cycle was determined by flow cytometry. ((b), (c)) Cells were treated with different doses of 𝛾-tocotrienol (2, 4, 8,
and 16𝜇mol/L) for the desired time. mRNA levels of Ki67 and PCNA were determined by real-time PCR. (d) Protein levels of PCNA were
determined byWestern blot. Data are expressed as mean ± SD (𝑛 = 3). ∗𝑝 < 0.05, compared to the control group. M: marker; B: blank control;
C: ethanol control.
3.2. Effect of 𝛾-Tocotrienol on the Differentiation of MC3T3-
E1 Cells. ALP is a homodimeric glycoprotein secreted by
osteoblasts, and the degree of secretion is related to the
degree of differentiation of the osteoblasts [43]. ALP secretion
is enhanced along with the process of osteoblasts differen-
tiation [44]. Therefore, the appearance of ALP activity is
an early phenotypic marker for osteogenic differentiation
of osteoblasts. In this study, ALP activity in MC3T3-E1
cells treated with 𝛾-tocotrienol for 24 h and 48 h did not
significantly change (data not shown here). However, it was
significantly increased from 15% to 194% in cells treated with
𝛾-tocotrienol at 4–16 𝜇mol/L for 72 h, when compared to
the control group (Figure 3(a)). Furthermore, ALP activity
in cells treated with 4𝜇mol/L of 𝛾-tocotrienol for 72 h was
significantly increased 1.55-fold when compared with control
cells (𝑝 < 0.05). The results suggested that 𝛾-tocotrienol
could promote osteoblast differentiation.
OC, ON, Col I, and Runx2 are major phenotypic markers
for preosteoblast differentiation during bone formation. OC
is the most specific gene for the osteoblast differentiation
and mineralization. OC is expressed during the postprolif-
erative period and reaches its maximum expression during
mineralization and accumulates in themineralized bone [45].
ON is synthesized by cells of the osteoblastic lineage, and
it also is a differentiation marker of bone cells [46]. Col I,
an important component of the bone extracellular matrix,
has been shown to be involved in the differentiation of the
osteoblast phenotype [47]. LiCl is able to increase osteoblast
differentiation [48]; thus it was used as a positive control. In
this study, the secretion levels of OC and ON in the super-
natants were shown in Figures 3(b) and 3(c). The treatment
with 𝛾-tocotrienol (2–8 𝜇mol/L) for 3 d and 6 d obviously
increased the secretion levels of both OC andON inMC3T3-
E1 cells. The maximal effect was observed in MC3T3-E1 cells
treated with 4 𝜇mol/L of 𝛾-tocotrienol, which increased OC
and ON secretion levels by 161.45% and 58.05% for 3 d and
122.97% and 69.77% for 6 d, respectively.Meanwhile, theCol I
mRNA levels in cells treatedwith 2–8𝜇mol/L of 𝛾-tocotrienol
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Figure 3: Effect of 𝛾-tocotrienol on the differentiation in MC3T3-E1 cells. Cells were treated with 𝛾-tocotrienol at different doses for the
desired time. The ALP activity (a), OC and ON amount ((b), (c)), and Col I mRNA level (d) were determined by colorimetric analysis,
ELISA, and real-time PCR analysis, respectively. Data are expressed as mean ± SD (𝑛 = 3). ∗𝑝 < 0.05 and ∗∗𝑝 < 0.01, compared to the control
group. B: blank control; C: ethanol control.
for 3 d were obviously increased compared with the control
cells (Figure 3(d)), and its protein level did not change in
comparison with the control cells (data not shown). The
result further confirmed that 𝛾-tocotrienol at low dosage can
stimulate osteoblast differentiation, and it also showed that 𝛾-
tocotrienolmay contribute to themineralization. In addition,
other findings indicate that 𝛾-tocotrienols delivered through
nanoemulsion exhibit superior antioxidant properties and
osteoblast differentiation [49], which is consistent with our
findings.
Runx2, a member of the runt family of transcription
factors, is important for osteoblast differentiation [50, 51].
In Runx2 knockout mice, no bone tissues or osteoblasts
are generated, which indicates that osteoblast differentiation
is completely blocked in the absence of Runx2 [52]. The
results showed that both the mRNA and protein level of
Runx2 (Figures 4(a) and 4(b)) were obviously upregulated
in MC3T3-E1 cells treated with 4 and 8𝜇mol/L of 𝛾-
tocotrienol for 72 h when compared with the control cells
(𝑝 < 0.05), which demonstrated that 𝛾-tocotrienol promoted
osteoblast differentiation by upregulation of the expression of
Runx2.
3.3. Effect of 𝛾-Tocotrienol on the Mineralization in Osteoblas-
ticMC3T3-E1Cells. Mineralization, an indispensable process
for bone formation, occurs in the last stage following col-
lagenous matrix maturation. It is a functional performance
of the further differentiation and maturation of the cells.
Osteoblasts are the main functional cells that promote bone
mineralization. Mineralized nodule formation is a symbol
of differentiation and maturation of osteoblasts and a mor-
phological manifestation of osteogenesis [53]. In order to
further clarify the effect of 𝛾-tocotrienol on mineralization
of osteoblasts, the level of mineralized nodule was observed
by using Alizarin Red staining method. The quantities of
Alizarin Red were analyzed by measuring the absorbance at
450 nm. As shown in Figure 5(a), the mineralized nodule
formation was lower in the control group. The number
of mineralized nodules was significantly increased in cells
treated with 2–8𝜇mol/L of 𝛾-tocotrienol for 24 days. The
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Figure 4: Effect of 𝛾-tocotrienol on mRNA and protein levels of Runx2 in MC3T3-E1 cells. Cells were treated with different doses of 𝛾-
tocotrienol for 72 h. The mRNA (a) and protein expression (b) of Runx2 were determined by real-time PCR and Western blot. Data are
expressed as mean ± SD (𝑛 = 3). ∗𝑝 < 0.05, compared to the control group. B: blank control; C: ethanol control.
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Figure 5: Effects of 𝛾-tocotrienol on the mineralization in MC3T3-E1 cells. Cells treated with different doses of 𝛾-tocotrienol for the desired
time. The mineralization in cells was determined by Alizarin Red staining. (a) Formation of mineralized nodule (100x). (b) Alizarin Red was
quantified by spectrophotometer. The results are expressed as means ± SD (𝑛 = 3). ∗∗𝑝 < 0.01, compared to the control group.
formation ofmineralized nodules was increased over 2.5-fold
in cells treated with 𝛾-tocotrienol at low concentration for
24 d compared with the control group (Figure 5(b)). No cells
could be observed in the 16𝜇mol/L tocotrienol-treated group,
which indicated that treatmentwith 16𝜇mol/L tocotrienol for
8 days or longer time showed a strong toxicity and inhibitory
effect on the mineralization of osteoblast. Our results suggest
that 𝛾-tocotrienol at low doses (2–8 𝜇mol/L) has a role in
promoting mineralization and inhibits bone formation at
doses of 16 𝜇mol/L or over.
4. Conclusions
In summary, the data in this study showed that 𝛾-tocotrienol
(2–8𝜇mol/L) could promote the proliferation, differentia-
tion, and mineralized nodule formation in MC3T3-E1 cells.
Meanwhile, our data also indicated that Runx2 protein may
be involved in the effect of 𝛾-tocotrienol on bone formation
through osteoblastic differentiation and subsequent mineral-
ization. 𝛾-Tocotrienol was effective for stimulating osteoblast
bone formation and it might be useful for prevention of
osteoporosis. However, the exact mechanism of 𝛾-tocotrienol
8 Journal of Chemistry
on proliferation and differentiation of osteoblasts needs fur-
ther investigation.
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